Gastric / GEJ adenocarcinoma · line 1 · Zolbetuximab + mFOLFOX6 (SPOTLIGHT) — 1L CLDN18.2-positive HER2-negative gastric/GEJ

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-ZOLBETUXIMAB-CHEMO`

ID	`IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMAB`
Type	Indication
Status	reviewed 2026-04-30 \| pending_clinical_signoff
Diseases	`DIS-GASTRIC`
Sources	`SRC-ESMO-GASTRIC-2024` `SRC-NCCN-GASTRIC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L for HER2-/MSS/CLDN18.2+ metastatic gastric/GEJ. NCCN cat 1 (2025); FDA Oct 2024. Bibliographic records SRC-SPOTLIGHT-SHITARA-2023 and SRC-GLOW (Shah Nat Med 2023) are available; claim-level linkage and UA access require review. named-patient pathway only.

Used By

Algorithms

ALGO-GASTRIC-METASTATIC-1L - ALGO-GASTRIC-METASTATIC-1L